The number of active cases are 66,308
SEC to hold meeting on Bharat Biotech's Nasal vaccine booster dose
After receiving the order from the Central Drugs Standard Control Organisation (CDSCO), the company started lifting unused stock from hospitals to re-label the shelf life from 9 months to 12 months
Bharat Biotech on Monday informed that India has supplied another batch of humanitarian assistance consisting of 5,00,000 doses of COVID-19 vaccine, Covaxin to Afghanistan.Taking to Twitter, Bharat Biotech said, "Today, India supplied the next batch of humanitarian assistance consisting of 5,00,000 doses of COVID vaccine (COVAXIN) to Afghanistan. The same was handed over to Indira Gandhi Hospital, Kabul."It also informed that another batch of additional 5,00,000 doses would be supplied in the coming weeks.The last batch of humanitarian assistance consisting of 5,00,000 doses of Covaxin was supplied to Afghanistan on January 1.India has committed to provide to Afghan people humanitarian assistance consisting of food grains, one million doses of COVID-19 vaccine and essential life-saving drugs.Earlier last month, India delivered 1.6 tons of medical assistance to Afghanistan through the World Health Organization (WHO).The Taliban took over control of Kabul on August 15 and following this
A total of 374 subjects reported either mild or moderate severity symptoms, with 78.6% getting resolved within a day, says Hyderabad-based vaccine maker
The clinical trials conducted on the paediatric population between June-September 2021 have shown robust safety, reactogenicity, and immunogenicity, says Hyderabad-based firm
Domestic demand had fallen after cases began to decline. Omicron surge may reverse the trend
The Hyderabad-based vaccine maker has already approached the Drug Controller General of India (DCGI) for approval to conduct phase-III trials of its intranasal vaccine
Telangana reports 12 new Omicron cases in the last 24 hours
Looks for global partners to produce and distribute vaccine - BBV154
Bharat Biotech has sought the approval of the Drug Controller General of India (DCGI) to conduct Phase 3 trials of its Covid-19 intranasal vaccine
The Hyderabad-based vaccine maker conducted phase 2 trials on 650 volunteers
The multi-dose vial policy saves money for procurement agencies by reducing the cold chain logistics
'We have submitted phase 3 clinical trial application to DCGI (Drugs Controller General of India)," a Bharat Biotech spokesperson said
Union Minister of State for Health Bharati Pravin Pawar shared the information through a written reply in Rajya Sabha
The Centre allowed commercial exports of Covaxin last week
India restarted on Friday exports of Covid-19 shots to COVAX for the first time since April
Experts say more real-world studies are required now
Bharat Biotech made 55 million doses of Covaxin in October, and aims to make 80 million doses in December.
Research does not estimate vaccine effectiveness against hospitalisation, severe disease, and death.